Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Urology Section, Durham VA Medical Center, Durham, NC, USA.
Prostate Cancer Prostatic Dis. 2023 Sep;26(3):461-474. doi: 10.1038/s41391-023-00710-1. Epub 2023 Aug 17.
Prostate cancer (PC) is the second most diagnosed cancer in men worldwide. While racial and ethnic differences exist in incidence and mortality, increasing data suggest outcomes by race among men with newly diagnosed PC are similar. However, outcomes among races beyond Black/White have been poorly studied. Moreover, whether outcomes differ by race among men who all have metastatic PC (mPC) is unclear. This systematic literature review (SLR) provides a comprehensive synthesis of current evidence relating race to survival in mPC.
An SLR was conducted and reported in accordance with PRISMA guidelines. MEDLINE®, Embase, and Cochrane Library using the Ovid® interface were searched for real-world studies published from January 2012 to July 2022 investigating the impact of race on overall survival (OS) and prostate cancer-specific mortality (PCSM) in patients with mPC. A supplemental search of key congresses was also conducted. Studies were appraised for risk of bias.
Of 3228 unique records identified, 62 records (47 full-text and 15 conference abstracts), corresponding to 54 unique studies (51 United States and 3 ex-United States) reporting on race and survival were included. While most studies showed no difference between Black vs White patients for OS (n = 21/27) or PCSM (n = 8/9), most showed that Black patients demonstrated improved OS on certain mPC treatments (n = 7/10). Most studies found no survival difference between White patients and Hispanic (OS: n = 6/8; PCSM: n = 5/6) or American Indian/Alaskan Native (AI/AN) (OS: n = 2/3; PCSM: n = 5/5). Most studies found Asian patients had improved OS (n = 3/4) and PCSM (n = 6/6) vs White patients.
Most studies found Black, Hispanic, and AI/AN patients with mPC had similar survival as White patients, while Black patients on certain therapies and Asian patients showed improved survival. Future studies are needed to understand what aspects of race including social determinants of health are driving these findings.
前列腺癌(PC)是全球男性中第二大常见的癌症。虽然在发病率和死亡率方面存在种族和民族差异,但越来越多的数据表明,新诊断为 PC 的男性的种族与预后相似。然而,在黑人和白人以外的其他种族中,这方面的数据研究较少。此外,在所有患有转移性前列腺癌(mPC)的男性中,种族是否会影响预后尚不清楚。本系统文献综述(SLR)全面综合了目前与 mPC 患者生存相关的种族研究证据。
根据 PRISMA 指南进行了 SLR,并进行了报道。使用 Ovid 界面在 MEDLINE®、Embase 和 Cochrane Library 上搜索了 2012 年 1 月至 2022 年 7 月发表的研究,这些研究调查了种族对 mPC 患者总体生存率(OS)和前列腺癌特异性死亡率(PCSM)的影响。还对重要会议进行了补充搜索。对研究进行了偏倚风险评估。
在 3228 条独特的记录中,有 62 条记录(47 篇全文和 15 篇会议摘要),对应于 54 项独特的研究(51 项来自美国,3 项来自美国以外),这些研究报告了种族与生存之间的关系。虽然大多数研究表明,在 OS(n=21/27)或 PCSM(n=8/9)方面,黑人患者与白人患者之间没有差异,但大多数研究表明,黑人患者在某些 mPC 治疗方法上的 OS 有所改善(n=7/10)。大多数研究发现,白人患者与西班牙裔(OS:n=6/8;PCSM:n=5/6)或美洲印第安人/阿拉斯加原住民(AI/AN)(OS:n=2/3;PCSM:n=5/5)之间的生存无差异。大多数研究发现,亚裔患者的 OS(n=3/4)和 PCSM(n=6/6)均优于白人患者。
大多数研究发现,患有 mPC 的黑种人、西班牙裔和 AI/AN 患者与白人患者的生存相似,而某些治疗方法的黑种人和亚裔患者的生存情况有所改善。需要进一步的研究来了解种族包括健康的社会决定因素的哪些方面导致了这些发现。